JAGSNPHARM.BO(JAGSNPHARM.BO)
$186.20▲1.35 (73.03%)
JAGSNPHARM.BO(JAGSNPHARM.BO)
BSE
$186.20▲1.35 (73.03%)
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Revenue Growth | +18.48% | +15.81% | +8.79% | -11.83% | +11.02% |
| Gross Profit Growth | +4.50% | +19.97% | +11.93% | -54.56% | +67.06% |
| EBITDA Growth | +127.60% | +20.64% | +30.42% | -12.65% | -14.73% |
| Operating Income Growth | +153.78% | +30.65% | +39.87% | -37.65% | +19.08% |
| Net Income Growth | +116.73% | +10.53% | +41.72% | -15.94% | -21.83% |
| EPS Growth | -13.33% | +10.77% | +41.67% | -16.67% | -21.51% |
| EPS Diluted Growth | -13.33% | +10.77% | +41.67% | -16.91% | -21.35% |
| Weighted Average Shares Growth | +0.00% | +0.00% | +0.00% | +1.35% | +0.36% |
| Weighted Average Shares Diluted Growth | +0.00% | +0.00% | +0.00% | +1.23% | -0.82% |
| Dividends per Share Growth | +100.00% | +299.96% | -100.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +150.93% | -80.16% | +733.39% | -24.62% | +2894.54% |
| Free Cash Flow Growth | +202.36% | -81.51% | +803.14% | -24.64% | +2882.65% |
| 10Y Revenue Growth (per Share) | +16.73% | +23.27% | +42.20% | +43.06% | N/A |
| 5Y Revenue Growth (per Share) | +30.93% | +51.24% | +87.03% | +23.43% | N/A |
| 3Y Revenue Growth (per Share) | +48.44% | +30.43% | +49.28% | +9.60% | N/A |
| 10Y Operating CF Growth (per Share) | +337.15% | -20.96% | +287.19% | +361.21% | N/A |
| 5Y Operating CF Growth (per Share) | +212.25% | +272.70% | +3059.78% | +12.29% | N/A |
| 3Y Operating CF Growth (per Share) | +1890.45% | -81.88% | +314.81% | +22.94% | N/A |
| 10Y Net Income Growth (per Share) | +137.59% | +152.86% | +1358.01% | +944.44% | N/A |
| 5Y Net Income Growth (per Share) | +424.19% | +58.92% | +331.28% | +207.14% | N/A |
| 3Y Net Income Growth (per Share) | +247.65% | +161.29% | +239.50% | +29.93% | N/A |
| 10Y Shareholders Equity Growth (per Share) | +31.23% | +32.89% | +61.52% | +87.43% | N/A |
| 5Y Shareholders Equity Growth (per Share) | +23.96% | +19.05% | +62.02% | +76.99% | N/A |
| 3Y Shareholders Equity Growth (per Share) | +24.33% | +25.25% | +43.10% | +51.65% | N/A |
| 10Y Dividend per Share Growth (per Share) | -19.99% | +699.98% | -100.00% | +886.05% | N/A |
| 5Y Dividend per Share Growth (per Share) | +900.00% | +3223.50% | -100.00% | +1873.18% | N/A |
| 3Y Dividend per Share Growth (per Share) | +899.76% | +1499.85% | -100.00% | +393.30% | N/A |
| Receivables Growth | -36.68% | +16.67% | +25.82% | -47.53% | +15.81% |
| Inventory Growth | +1.36% | +0.06% | -30.48% | -27.47% | -5.66% |
| Asset Growth | +11.74% | +2.59% | +15.73% | +11.35% | +15.81% |
| Book Value per Share Growth | +9.81% | +7.32% | +21.42% | +16.37% | +27.81% |
| Debt Growth | +45.51% | -22.70% | +14.38% | +48.98% | -9.97% |
| R&D Expense Growth | +124.40% | -100.00% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | -8.97% | +49.42% | -4.39% | -17.36% | -51.85% |